2347 related articles for article (PubMed ID: 17721190)
21. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
22. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology.
Varma M; Morgan M; Jasani B; Tamboli P; Amin MB
Am J Clin Pathol; 2002 Aug; 118(2):202-7. PubMed ID: 12162678
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer-associated markers.
Chu TM
Immunol Ser; 1990; 53():339-56. PubMed ID: 1713065
[TBL] [Abstract][Full Text] [Related]
24. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
[TBL] [Abstract][Full Text] [Related]
25. Prostatic adenocarcinoma metastases mimicking small cell carcinoma on fine-needle aspiration.
Parwani AV; Ali SZ
Diagn Cytopathol; 2002 Aug; 27(2):75-9. PubMed ID: 12203872
[TBL] [Abstract][Full Text] [Related]
26. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
27. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.
Chen G; Shukeir N; Potti A; Sircar K; Aprikian A; Goltzman D; Rabbani SA
Cancer; 2004 Sep; 101(6):1345-56. PubMed ID: 15316903
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor status of lymph node metastases from prostate cancer.
Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
Prostate; 1996 Feb; 28(2):129-35. PubMed ID: 8604394
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor.
Frković-Grazio S; Kraljić I; Trnski D; Tarle M
Anticancer Res; 1994; 14(5B):2151-6. PubMed ID: 7840515
[TBL] [Abstract][Full Text] [Related]
30. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
Ersev A; Ersev D; Turkeri L; Ilker Y; Simsek F; Kullu S; Akdas A
Prog Clin Biol Res; 1990; 357():129-34. PubMed ID: 1699237
[TBL] [Abstract][Full Text] [Related]
31. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
32. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
[TBL] [Abstract][Full Text] [Related]
33. [Immunohistochemical study of neuroendocrine cells and prostate-specific antigen in prostate carcinoma].
Yao GY; Lai MD; Chen PH
Zhonghua Yi Xue Za Zhi; 1994 Mar; 74(3):161-2, 191-2. PubMed ID: 7522941
[TBL] [Abstract][Full Text] [Related]
34. The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis.
Quick CM; Gokden N; Sangoi AR; Brooks JD; McKenney JK
Hum Pathol; 2010 Aug; 41(8):1145-9. PubMed ID: 20413145
[TBL] [Abstract][Full Text] [Related]
35. Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features.
Lane Z; Epstein JI; Ayub S; Netto GJ
Hum Pathol; 2008 Apr; 39(4):543-9. PubMed ID: 18234278
[TBL] [Abstract][Full Text] [Related]
36. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.
Kristiansen G; Pilarsky C; Pervan J; Stürzebecher B; Stephan C; Jung K; Loening S; Rosenthal A; Dietel M
Prostate; 2004 Feb; 58(2):183-92. PubMed ID: 14716744
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.
Beckett ML; Lipford GB; Haley CL; Schellhammer PF; Wright GL
Cancer Res; 1991 Feb; 51(4):1326-33. PubMed ID: 1705172
[TBL] [Abstract][Full Text] [Related]
38. Cytology of metastatic adenocarcinoma of the prostate in pleural effusions.
Renshaw AA; Nappi D; Cibas ES
Diagn Cytopathol; 1996 Aug; 15(2):103-7. PubMed ID: 8872430
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen-positive extramammary Paget's disease--association with prostate cancer.
Hammer A; Hager H; Steiniche T
APMIS; 2008 Jan; 116(1):81-8. PubMed ID: 18254784
[TBL] [Abstract][Full Text] [Related]
40. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
